NCT00499603 - Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2017

Conditions

Breast Cancer

Interventions

DRUG

Paclitaxel

80 mg/m\^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.

DRUG

5-Fluorouracil

500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.

DRUG

Epirubicin

100 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.

DRUG

Cyclophosphamide

500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.

DRUG

RAD001

30 mg by mouth weekly on Days 1, 8, \& 15 for 12 cycles.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston